Last reviewed · How we verify
Matched Placebo (Capsules)
Matched Placebo (Capsules) is a Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved.
Matched placebo is an inert capsule formulation designed to mimic an active pharmaceutical agent for use as a control in clinical trials.
Matched placebo capsules contain inert ingredients designed to mimic the appearance and administration of an active pharmaceutical agent for use in blinded clinical trials. Used for Clinical trial control comparator (non-therapeutic).
At a glance
| Generic name | Matched Placebo (Capsules) |
|---|---|
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Matched placebo capsules are manufactured to be identical in appearance, size, taste, and other sensory characteristics to the active drug being tested, allowing for blinded clinical trial designs. They contain no pharmacologically active ingredients and serve as the control arm to isolate the true therapeutic effect of the investigational drug from placebo response and natural disease progression.
Approved indications
Common side effects
Key clinical trials
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 (PHASE3)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (PHASE3)
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matched Placebo (Capsules) CI brief — competitive landscape report
- Matched Placebo (Capsules) updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI
Frequently asked questions about Matched Placebo (Capsules)
What is Matched Placebo (Capsules)?
How does Matched Placebo (Capsules) work?
Who makes Matched Placebo (Capsules)?
What development phase is Matched Placebo (Capsules) in?
Related
- Manufacturer: Johns Hopkins University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing